NEW YORK, Oct. 26, 2009 (Lawfuel NEWSWIRE) — The Brualdi Law Firm, P.C.
announces that a lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of Hansen Medical, Inc. (“Hansen” or the “Company”)
(Nasdaq:HNSN) stock during the period between May 1, 2008, through October 18, 2009 (the “Class Period”) for violations of the federal securities laws.
No class has yet been certified in the above action. Until a class is certified, you are not represented by counsel unless you retain one. If you purchased Hansen common stock during the Class Period, and wish to move the court for appointment of lead plaintiff, you must do so by December 22, 2009. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the Company during the Class Period. You do not need to seek appointment as a lead plaintiff in order to share in any recovery.
To be a member of the class you need not take any action at this time, and you may retain counsel of your choice. If you wish to discuss this action or have any questions concerning this Notice or your rights or interests with respect to these matters, please contact Sue Lee at The Brualdi Law Firm, P.C. 29 Broadway, Suite 2400, New York, New York 10006, by telephone toll free at (877) 495-1187 or (212) 952-0602, by email to [email protected] or visit our website at http://www.brualdilawfirm.com.
The Complaint alleges that throughout the Class Period defendants knew or recklessly disregarded that their public statements concerning Hansen’s business, operations and prospects were materially false and misleading. Specifically, the defendants made false and/or misleading statements and/or failed to disclose: (1) that the Company improperly recognized revenue; (2) that, as a result, the Company’s revenue and financial results were overstated during the Class Period; (3) that the Company’s financial results were not prepared in accordance with Generally Accepted Accounting Principles (“GAAP”); (4) that the Company lacked adequate internal and financial controls; and (5) that, as a result of the above, the Company’s financial statements were materially false and misleading at all relevant times.